Vir Biotechnology
208 hedge funds and large institutions have $652M invested in Vir Biotechnology in 2024 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 69 increasing their positions, 69 reducing their positions, and 29 closing their positions.
141% more call options, than puts
Call options by funds: $9.81M | Put options by funds: $4.07M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
45% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 29
32% more capital inflows, than outflows
Capital inflows: $97.2M | Capital outflows: $73.7M
6% more funds holding
Funds holding: 197 → 208 (+11)
0.35% more ownership
Funds ownership: 64.11% → 64.47% (+0.35%)
0% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$8.55M |
| 2 |
SCM
Sio Capital Management
New York
|
+$8.32M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$7.24M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$7.08M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$17.8M |
| 2 |
Jefferies Financial Group
New York
|
-$8.13M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.34M |
| 4 |
D.E. Shaw & Co
New York
|
-$3.38M |
| 5 |
OrbiMed
New York
|
-$2.8M |
VIR Hedge Fund Activity: Q4 2024 in Review
208 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q4 2024, worth a combined $652M — down 0.64% from $656M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new VIR positions and 29 closed out — a net gain of 13 holders — while 69 added to existing stakes and 69 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $8.55M. The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $17.8M sold.
- 208 institutional investors held Vir Biotechnology (VIR) as of Q4 2024, up from 197 in Q3 2024.
- Funds reported $652M of Vir Biotechnology stock for Q4 2024, down 0.64% quarter-over-quarter.
- 42 funds opened new Vir Biotechnology positions in Q4 2024 and 29 closed out, a net change of +13 holders.
- The largest Vir Biotechnology buyer in Q4 2024 was Baker Bros. Advisors, an estimated $8.55M added.
- The largest Vir Biotechnology seller in Q4 2024 was Baillie Gifford & Co, an estimated $17.8M sold.
Based on aggregated 13F filings for Q4 2024.